This study investigates the use of adoptive cell therapy for patients with metastatic melanoma, a type of skin cancer that has spread to other parts of the body. The therapy involves using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight the cancer. Before receiving the TILs, patients undergo a process called lymphodepletion to reduce their immune cells, making space for the new cells.

Participants in this study will receive a treatment that includes the infusion of their own TILs followed by a drug called interleukin 2 (IL-2) that helps boost the immune response. The study involves a preparatory treatment to get the body ready for the TIL infusion, followed by the IL-2 regimen.

• Who can participate: Adults with unresectable or metastatic melanoma, who have no other effective treatment options, may be eligible. Participants must have adequate organ function and be able to complete all study procedures. They must also agree to use birth control if they or their partners are of childbearing potential. Individuals with certain conditions, such as HIV, may be excluded.
• Study details: Participants will undergo a lymphocyte depleting regimen, which involves reducing certain immune cells before receiving their own TILs, followed by interleukin 2 (IL-2) treatment. A placebo is not used in this study.